Publication | Open Access

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Breast OncologyMedicinePathologyPik3ca MutationsCancer GenomicsBreast CancerProspective TrialsCancer TreatmentCancer GeneticsOncologyRadiation Oncology